HomeCompareJMHLY vs ABBV

JMHLY vs ABBV: Dividend Comparison 2026

JMHLY yields 3.17% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JMHLY wins by $82.8K in total portfolio value· pulled ahead in Year 7
10 years
JMHLY
JMHLY
● Live price
3.17%
Share price
$71.97
Annual div
$2.28
5Y div CAGR
47.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$185.1K
Annual income
$80,475.19
Full JMHLY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — JMHLY vs ABBV

📍 JMHLY pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodJMHLYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, JMHLY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
JMHLY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

JMHLY
Annual income on $10K today (after 15% tax)
$269.28/yr
After 10yr DRIP, annual income (after tax)
$68,403.91/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, JMHLY beats the other by $47,347.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of JMHLY + ABBV for your $10,000?

JMHLY: 50%ABBV: 50%
100% ABBV50/50100% JMHLY
Portfolio after 10yr
$143.7K
Annual income
$52,623.47/yr
Blended yield
36.62%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

JMHLY
Analyst Ratings
2
Buy
Consensus: Buy
Price Target
$43.75
-39.2% upside vs current
Range: $40.50 — $47.00
Altman Z
1.5
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

JMHLY buys
0
ABBV buys
0
No recent congressional trades found for JMHLY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricJMHLYABBV
Forward yield3.17%3.06%
Annual dividend / share$2.28$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR47.2%40.6%
Portfolio after 10y$185.1K$102.3K
Annual income after 10y$80,475.19$24,771.77
Total dividends collected$153.3K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$43.75$256.15

Year-by-year: JMHLY vs ABBV ($10,000, DRIP)

YearJMHLY PortfolioJMHLY Income/yrABBV PortfolioABBV Income/yrGap
1$11,166$466.33$11,550$430.00$384.00ABBV
2$12,664$716.35$13,472$627.96$808.00ABBV
3$14,669$1,117.69$15,906$926.08$1.2KABBV
4$17,476$1,780.94$19,071$1,382.55$1.6KABBV
5$21,619$2,919.01$23,302$2,095.81$1.7KABBV
6$28,099$4,967.51$29,150$3,237.93$1.1KABBV
7← crossover$38,949$8,882.44$37,536$5,121.41+$1.4KJMHLY
8$58,613$16,937.67$50,079$8,338.38+$8.5KJMHLY
9$97,781$35,065.22$69,753$14,065.80+$28.0KJMHLY
10$185,101$80,475.19$102,337$24,771.77+$82.8KJMHLY

JMHLY vs ABBV: Complete Analysis 2026

JMHLYStock

Jardine Matheson Holdings Limited, through its subsidiaries, engages in the motor vehicles and related operations, property investment and development, food retailing, health and beauty, home furnishings, engineering and construction, and transportation businesses. It is also involved in the restaurants and hotels, financial services, heavy equipment, mining, and agribusinesses. The company offers airport ground handling, and aviation and transport services; and engineering, sourcing, and contracting services, as well as owns and operates air cargo terminals, and invests in residential properties. It is also involved in the Pizza Hut and KFC franchise restaurants operations; designing, engineering, installation, maintenance, and modernization of escalators, and moving walkways; and supplying aseptic packaging materials. In addition, the company provides automobile and motorcycle products, as well as sells and services motor vehicles; invests in, owns, develops, and manages office and retail properties; operates outlets, including supermarkets, hypermarkets, convenience stores, health and beauty stores, and home furnishings stores; and invests in and manages a portfolio of deluxe and first class hotels, resorts, and residences. Further, it engages in the motor dealerships, dairy, and cement businesses. Additionally, the company is involved in the energy, infrastructure, logistics, insurance brokerage, and information technology businesses. It operates in China, Southeast Asia, the United Kingdom, and internationally. The company was founded in 1832 and is based in Hamilton, Bermuda.

Full JMHLY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this JMHLY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

JMHLY vs SCHDJMHLY vs JEPIJMHLY vs OJMHLY vs KOJMHLY vs MAINJMHLY vs JNJJMHLY vs MRKJMHLY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.